Human normal Immunoglobulin

Welcome to Dwaey, specifically on Human normal Immunoglobulin page.
This medicine contains important and useful components, as it consists of
Human normal Immunoglobulin is available in the market in concentration.

Generic Name of Human normal Immunoglobulin - Learn More

Human normal Immunoglobulin

Human normal Immunoglobulin Precaution - What You Need to Know

Before using Human Normal Immunoglobulin (HNIG), it is crucial that patients consult their healthcare provider to assess the suitability of the treatment, particularly for individuals with specific health conditions. Some important precautions include:

- Hypersensitivity Reactions: People with a history of allergic reactions to immunoglobulins or components used in the formulation (e.g., gelatin, polysorbate) should avoid using HNIG. Severe allergic reactions such as anaphylaxis are rare but possible. Immediate medical help should be sought if symptoms like hives, swelling, or difficulty breathing occur.
- Renal Impairment: HNIG may cause renal dysfunction or renal failure, especially in patients with preexisting kidney conditions or those receiving high doses. Renal function should be monitored closely in at-risk patients, particularly in elderly patients, those with diabetes, or those using loop diuretics.
- Thromboembolic Events: Patients with risk factors for blood clots (e.g., deep vein thrombosis (DVT), pulmonary embolism (PE)) should use HNIG cautiously, as it can increase the risk of thromboembolic events.
- Transmission of Infectious Diseases: While Human Normal Immunoglobulin is carefully screened for viruses, there is still a small risk of transmitting infectious diseases. It should not be used in immunocompromised individuals who are at heightened risk.
- Hyperviscosity Syndrome: High doses of HNIG can result in increased viscosity (thickness of blood), which can be problematic for patients with cardiovascular conditions. Special care should be taken when administering large volumes.

Human normal Immunoglobulin Indication - Uses and Benefits

Human Normal Immunoglobulin (HNIG) is primarily used for:

- Primary Immunodeficiency Disorders: HNIG is used to treat patients with primary immunodeficiency (e.g., common variable immunodeficiency or X-linked agammaglobulinemia) who have difficulty producing normal antibodies. It helps provide the necessary immunoglobulins (antibodies) to protect against infections.
- Hypogammaglobulinemia: It is used in patients with hypogammaglobulinemia, a condition where there is low serum immunoglobulin due to various causes (e.g., chronic lymphocytic leukemia, myeloma).
- Autoimmune Disorders: HNIG is also indicated for treating certain autoimmune conditions such as immune thrombocytopenic purpura (ITP), where it helps increase platelet counts and reduce the immune response against platelets.
- Guillain-Barré Syndrome: It is used as part of the treatment for Guillain-Barré syndrome (GBS), an autoimmune disorder where the body attacks the nerves, leading to muscle weakness or paralysis.
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): This is a disorder involving nerve inflammation that can be treated with HNIG to reduce symptoms and progression.
- Kawasaki Disease: HNIG is used to treat Kawasaki disease, a condition in children characterized by fever, rash, and inflammation of blood vessels.

Human normal Immunoglobulin Contraindications - Important Warnings

Human Normal Immunoglobulin should not be used in the following conditions:

- Hypersensitivity to Immunoglobulin: HNIG is contraindicated in patients with severe hypersensitivity reactions to human immunoglobulin or any of the product's components.
- Selective IgA Deficiency: In rare cases, individuals with IgA deficiency who have developed anti-IgA antibodies may be at increased risk of severe reactions to HNIG, and its use is generally avoided.
- Severe Renal Impairment: HNIG is contraindicated in patients with severe renal impairment or renal failure, as the product can worsen kidney function.
- Hypercoagulable States: In individuals with certain thrombotic disorders, the use of HNIG should be avoided due to the increased risk of thrombosis.

Human normal Immunoglobulin Side Effects - What to Expect

The side effects of Human Normal Immunoglobulin are generally rare, but can include:

- Common Side Effects:
- Headache
- Fever
- Chills
- Fatigue
- Mild pain or swelling at the injection site
- Rash

- Serious Side Effects:
- Anaphylaxis: Although rare, severe allergic reactions (e.g., difficulty breathing, swelling of the face or throat) can occur. This is more likely in individuals with prior sensitivities to immunoglobulins.
- Thromboembolic Events: Increased risk of blood clots, deep vein thrombosis (DVT), or pulmonary embolism (PE) can occur, especially in those with risk factors for cardiovascular disease.
- Renal Failure: HNIG has been linked to acute renal failure in rare cases, particularly in those with preexisting kidney conditions or those receiving high doses.
- Hemolysis: Destruction of red blood cells (hemolysis) can occur in some patients after the infusion, especially in those with underlying hemolytic anemia.

Patients receiving HNIG should report any unusual symptoms, such as swelling, shortness of breath, or blood in urine, to their healthcare provider immediately.

Human normal Immunoglobulin Pregnancy Category ID - Safety Information

3

Human normal Immunoglobulin Mode of Action - How It Works

Human Normal Immunoglobulin works by providing the body with a concentrated source of immunoglobulins (IgG), which are essential for fighting infections. Immunoglobulins are antibodies produced by the body’s immune system in response to pathogens. When administered, HNIG helps to:

- Boost Immune Function: The immunoglobulins in HNIG provide immediate protection by binding to foreign antigens (e.g., bacteria, viruses) and neutralizing them.
- Provide Passive Immunity: For individuals with immunodeficiency or those unable to produce sufficient antibodies, HNIG provides the necessary immune protection until their own immune system can recover or become more active.
- Modulate Immune Response: In certain autoimmune diseases, HNIG works to modulate the abnormal immune response, helping to reduce inflammation and autoimmune activity.

Human normal Immunoglobulin Drug Interactions - What to Avoid

HNIG may interact with several drugs and conditions, affecting its efficacy or safety:

- Live Vaccines: HNIG can interfere with the efficacy of live vaccines (e.g., measles, mumps, rubella, and varicella). The immune globulin may reduce the effectiveness of live vaccines if given concurrently. It is advised to avoid live vaccines for up to 3 months after receiving immunoglobulin.
- Other Immunoglobulins: If other immunoglobulins are administered simultaneously or close to the time of HNIG infusion, the risk of an immune reaction may increase.
- Blood Thinners (Anticoagulants): HNIG may interact with medications that affect blood clotting, increasing the risk of thrombosis. Patients on anticoagulants should be monitored closely.
- Diuretics: Concurrent use of loop diuretics (e.g., furosemide) may increase the risk of renal dysfunction when combined with HNIG.
- Immunosuppressive Drugs: Patients on immunosuppressive therapy (e.g., corticosteroids, cytotoxic drugs) should be monitored as they might be more prone to infections despite receiving immunoglobulin therapy.

Human normal Immunoglobulin Adult Dose - Recommended Dosage

The recommended dose of Human Normal Immunoglobulin varies depending on the condition being treated:

- Primary Immunodeficiency: The typical dose is 300-600 mg/kg body weight administered every 3-4 weeks. The exact dose depends on the individual’s clinical condition and response.
- Guillain-Barré Syndrome: A typical treatment regimen includes 0.4 g/kg/day for 5 days.
- Immune Thrombocytopenic Purpura (ITP): The standard dose is 0.8-1 g/kg body weight administered once or in divided doses over 2-5 days.
- Kawasaki Disease: A dose of 2 g/kg body weight is administered as a single infusion.

Human normal Immunoglobulin Child Dose - Dosage for Children

The pediatric dose of HNIG varies depending on the condition being treated:

- Primary Immunodeficiency: The usual dose is 300-600 mg/kg body weight every 3-4 weeks.
- Guillain-Barré Syndrome: In children, the typical dose is 0.4 g/kg/day for 5 days.
- Immune Thrombocytopenic Purpura (ITP): The usual pediatric dose is 0.8-1 g/kg body weight administered once or in divided doses over 2-5 days.

As always, the dose for children should be determined by a healthcare provider based on the specific medical condition and clinical response.

Human normal Immunoglobulin Renal Dose - Dosage for Kidney Conditions

For patients with renal impairment, special caution is required. Renal function should be monitored, and doses may need to be adjusted. In patients with severe renal dysfunction, the use of HNIG is generally contraindicated. For those with mild to moderate kidney issues, dosing adjustments and close monitoring are recommended to avoid renal damage.